Sachs David C. 4
4 · ImmunityBio, Inc. · Filed Feb 12, 2026
Research Summary
AI-generated summary of this filing
ImmunityBio (IBRX) CFO David C. Sachs Receives RSU Award, Shares Withheld
What Happened
David C. Sachs, Chief Financial Officer of ImmunityBio, had 82,236 restricted stock units (RSUs vest) on February 10, 2026. The RSUs converted into common shares (reported as an exercise/conversion of a derivative at $0). To cover tax withholding, 42,643 shares were surrendered at a settlement price of $6.93 for a withholding value of $295,516. Net shares retained from the vesting event were 39,593, worth approximately $274,379 (based on the $6.93 price).
Key Details
- Transaction date: February 10, 2026; Form filed February 12, 2026 (timely filing).
- Vesting/settlement price: $6.93 (closing price used from February 9, 2026).
- Gross shares issued on vesting: 82,236 shares (value ≈ $569,895).
- Shares withheld for taxes: 42,643 shares (value $295,516).
- Net shares retained: 39,593 shares (value ≈ $274,379).
- Footnotes: Each RSU converts to one share; vesting occurred per the award schedule (vesting commencement Feb 10, 2025 with annual installments of ~33.33%/33.33%/33.34%).
- Shares owned after the transaction: not specified in the filing.
- Transaction codes: M = conversion/exercise of derivative (RSU settlement); F = shares withheld to satisfy tax liability.
Context
This was a scheduled RSU vesting event (award settlement) rather than an open-market purchase or discretionary sale. The disposition of shares here reflects tax withholding—common practice when equity awards vest—and does not necessarily indicate a broader buy/sell signal. The filing appears timely and consistent with routine equity compensation mechanics.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-10+82,236→ 322,818 total - Tax Payment
Common Stock
[F2]2026-02-10$6.93/sh−42,643$295,516→ 280,175 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-02-10−82,236→ 164,474 total→ Common Stock (82,236 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
- [F2]On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld.
- [F3]Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.